
Sign up to save your podcasts
Or


Let us know your thoughts. We would love to hear from you.
Dr Christopher Cannon discusses the EVOLVE-MI trial to decrease cholesterol with Evolocumab early after Myocardial Infarction as well as the rational for a less intensive way to study patients with open label, pragmatic clinical trials.
By Thomas Nero, MD5
33 ratings
Let us know your thoughts. We would love to hear from you.
Dr Christopher Cannon discusses the EVOLVE-MI trial to decrease cholesterol with Evolocumab early after Myocardial Infarction as well as the rational for a less intensive way to study patients with open label, pragmatic clinical trials.